NCT00378300

Brief Summary

The purpose of this study is to study the clinical effects of taking probiotics in patients who have moderate to severe atopic dermatitis. There has been several studies showing improvement in the severity of atopic dermatitis after taking probiotics. The mechanism of this improvement is currently unknown. We propose that probiotics improve atopic dermatitis by stimulating, or increasing, the activity of a special type of cell called the T Regulatory cell--which can suppress the activity of allergic disease.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Jul 2007

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 18, 2006

Completed
1 day until next milestone

First Posted

Study publicly available on registry

September 19, 2006

Completed
10 months until next milestone

Study Start

First participant enrolled

July 1, 2007

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2008

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2008

Completed
Last Updated

March 16, 2016

Status Verified

March 1, 2016

Enrollment Period

11 months

First QC Date

September 18, 2006

Last Update Submit

March 14, 2016

Conditions

Keywords

Atopic DermatitisProbioticsT Regulatory Cells

Outcome Measures

Primary Outcomes (2)

  • SCORAD Score change taken at baseline and after 1 month of either probiotic or placebo

  • T Regulatory cell activity change taken at baseline and after 1 month of either probiotic or placebo

Secondary Outcomes (3)

  • Dermatitis Family Impact Questionnaire change taken at baseline and after 1 month of either probiotic or placebo

  • T Regulatory cell activity when exposed to probiotics in vitro

  • Change in Serum IgE or IgG levels taken at baseline and after 1 month of either probiotic or placebo

Interventions

Eligibility Criteria

Age6 Months - 3 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)

You may qualify if:

  • Age between 6 months to 3 years
  • Physician diagnosis of moderate to severe atopic dermatitis as defined by the Hanifin and Rajka criteria
  • Ability to take enterally commercially available probiotics by powder form added to food or drink
  • Ability to undergo venipuncture or dermal puncture (if less than 1 year old)

You may not qualify if:

  • Prior exposure to probiotics
  • Current antibiotic administration
  • Known history of chronic medical condition such as congenital heart disease, liver or kidney disease, or immune deficiency
  • Absence of T regulatory cell induction by probiotic bacteria on initial laboratory assessment
  • Any other condition in which the Investigators involved in the study determine potential subject is unsuitable for the study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

UCLA Medical Center

Los Angeles, California, 90095, United States

Location

Related Publications (8)

  • Kalliomaki M, Salminen S, Arvilommi H, Kero P, Koskinen P, Isolauri E. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet. 2001 Apr 7;357(9262):1076-9. doi: 10.1016/S0140-6736(00)04259-8.

    PMID: 11297958BACKGROUND
  • Isolauri E, Arvola T, Sutas Y, Moilanen E, Salminen S. Probiotics in the management of atopic eczema. Clin Exp Allergy. 2000 Nov;30(11):1604-10. doi: 10.1046/j.1365-2222.2000.00943.x.

    PMID: 11069570BACKGROUND
  • Pessi T, Sutas Y, Hurme M, Isolauri E. Interleukin-10 generation in atopic children following oral Lactobacillus rhamnosus GG. Clin Exp Allergy. 2000 Dec;30(12):1804-8. doi: 10.1046/j.1365-2222.2000.00948.x.

    PMID: 11122221BACKGROUND
  • Kalliomaki M, Salminen S, Poussa T, Arvilommi H, Isolauri E. Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial. Lancet. 2003 May 31;361(9372):1869-71. doi: 10.1016/S0140-6736(03)13490-3.

    PMID: 12788576BACKGROUND
  • Rosenfeldt V, Benfeldt E, Nielsen SD, Michaelsen KF, Jeppesen DL, Valerius NH, Paerregaard A. Effect of probiotic Lactobacillus strains in children with atopic dermatitis. J Allergy Clin Immunol. 2003 Feb;111(2):389-95. doi: 10.1067/mai.2003.389.

    PMID: 12589361BACKGROUND
  • Weston S, Halbert A, Richmond P, Prescott SL. Effects of probiotics on atopic dermatitis: a randomised controlled trial. Arch Dis Child. 2005 Sep;90(9):892-7. doi: 10.1136/adc.2004.060673. Epub 2005 Apr 29.

    PMID: 15863468BACKGROUND
  • Viljanen M, Savilahti E, Haahtela T, Juntunen-Backman K, Korpela R, Poussa T, Tuure T, Kuitunen M. Probiotics in the treatment of atopic eczema/dermatitis syndrome in infants: a double-blind placebo-controlled trial. Allergy. 2005 Apr;60(4):494-500. doi: 10.1111/j.1398-9995.2004.00514.x.

    PMID: 15727582BACKGROUND
  • Smits HH, Engering A, van der Kleij D, de Jong EC, Schipper K, van Capel TM, Zaat BA, Yazdanbakhsh M, Wierenga EA, van Kooyk Y, Kapsenberg ML. Selective probiotic bacteria induce IL-10-producing regulatory T cells in vitro by modulating dendritic cell function through dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin. J Allergy Clin Immunol. 2005 Jun;115(6):1260-7. doi: 10.1016/j.jaci.2005.03.036.

    PMID: 15940144BACKGROUND

MeSH Terms

Conditions

Dermatitis, Atopic

Interventions

Probiotics

Condition Hierarchy (Ancestors)

Skin Diseases, GeneticGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesDermatitisSkin DiseasesSkin and Connective Tissue DiseasesSkin Diseases, EczematousHypersensitivity, ImmediateHypersensitivityImmune System Diseases

Intervention Hierarchy (Ancestors)

Dietary SupplementsFoodDiet, Food, and NutritionPhysiological PhenomenaFood and Beverages

Study Officials

  • Michael H Land, MD

    University of California, Los Angeles

    PRINCIPAL INVESTIGATOR
  • Martin G Martin, MD, MPP

    University of California, Los Angeles

    PRINCIPAL INVESTIGATOR
  • Robert L Roberts, MD, PhD

    University of California, Los Angeles

    PRINCIPAL INVESTIGATOR
  • Tatiana Hernandez

    University of California, Los Angeles

    STUDY DIRECTOR
0

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

September 18, 2006

First Posted

September 19, 2006

Study Start

July 1, 2007

Primary Completion

June 1, 2008

Study Completion

June 1, 2008

Last Updated

March 16, 2016

Record last verified: 2016-03

Locations